Elan Licenses Its NanoCrystal Technology to Roche
Proprietary Elan technology helps improve drug delivery by transforming drugs into more effective and 'user friendly' dosage forms to increase patient convenience and compliance
22-Apr-2004 -
Athlone, Ireland. Elan Pharma International Ltd., a subsidiary of Elan Corporation plc, announced an agreement to license its proprietary NanoCrystal(TM) technology to Roche. NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that ...
bioavailability
drug delivery
Elan
+8